Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a recent randomized clinical trial backed by Lilly
8 Wegovy approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
Regarding rosiglitazone, RCTs demonstrated a biochemical improvement in liver enzymes and glycemic control both in diabetic and non-diabetic patients with NAFLD, whereas evidence of histological improvement is less clear: results derived from different studies are controversial regarding the effect on steatosis, ballooning, and fibrosis [45, 46, 57, 58]
Esto no solo mejora el control metablico y reduce la carga heptica, sino que tambin puede disminuir el riesgo de progresin a cirrosis y otras complicaciones graves